Effects of small intestinal L-glutamate and L-glutamine infusions on gut motility, gut hormone release and blood glucose control in healthy humans.

Not Applicable

Completed

• Conditions: Obesity; Healthy human physiology; Diet and Nutrition - Obesity; Oral and Gastrointestinal - Normal oral and gastrointestinal development and function

• Registration Number: ACTRN12612000826842
• Lead Sponsor: Christine Feinle-Bisset

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

A total of 20 Caucasian male and female (BMI 18-25 kg/m2) subjects, aged between 18 - 50 years, will be included in the study. All subjects will be required to be weight-stable (i.e. less than 5 % fluctuation in their body weight) at study entry, as determined by their self-reported weight in the preceding 3 months, and will be required to maintain their normal physical activity over the course of the study.

Exclusion Criteria

Significant gastrointestinal symptoms, disease or surgery, use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, body weight or appetite (eg domperidone and cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)
lactose intolerance/ MSG intolerance/other food allergy(ies), current gallbladder or pancreatic disease, diabetes mellitus, as defined by fasting glucose greater than 6.9 mmol/l and/or glycated haemoglobin equal to 6.2 %, cardiovascular or respiratory diseases, individuals with low ferritin levels (females less than 15 ng/mL, males less than 30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study, any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above), high performance athletes, current intake of greater than 2 standard drinks on greater than 5 days per week, current smokers of cigarettes/cigars/marijuana, current intake of any illicit substance, vegetarians. In female subjects, pregnancy or lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Antropyloroduodenal motility (number of antral, duodenal and isolated pyloric pressure waves, and basal pyloric pressure.[Using a manomentry assembly and catheter, antropyloroduodenal pressures will be continously monitored from intubation until 90minutes (end of infusion) for all four infusion sessions.];Plasma concentrations of gastrointestinal hormones (e.g. CCK, GLP-1, PYY, GIP and ghrelin, and potentially other, yet to be identified gut hormones), insulin and glucose.[Gut hormone release will be assessed by enzyme-linked immunosorbent assay (ELIZA) or radio immunosorbent assay (RIA) from blood samples taken at t= -10, 0, 15, 30, 45, 60, 75, 90 and 120 minutes, in each of the four sesssions.]

Secondary Outcome Measures

Name	Time	Method
Appetite sensations using a Visual Analogue Scale (VAS) (satiety, hunger, fullness, thrist, desire to eat and amount of food desire to eat) and macronutrient and total energy intake and the buffet meal[VAS questionnaires are taken at = -10, 0, 15, 30, 45, 60, 75, 90 and 120 minutes, at each of the four sessions. The buffet meal will be presented at 90 mins when the infusion ends and the subject will be allowed to freely consume food until comfortable full for 30 mins (until t=120mins)]